FATE THERAPEUTICS INC cotiza a 2.13 USD y tiene una capitalización bursátil de $255M. En los últimos 12 meses ha facturado $6M con un margen de flujo de caja libre del -1685.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-0.26 | $-0.27 |
| Estimado | $-0.25 | $-0.26 | $-0.28 | $-0.27 |
| Sorpresa | — | — | +7.1% | +0.0% |
| Métrica | FATE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -2222.4% | -38.6% | -2183.8% |
| Net Margin | -2051.1% | -33.6% | -2017.5% |
| FCF Margin | -1685.8% | -13.9% | -1671.9% |
| ROE | -65.8% | -40.4% | -25.4% |
| ROA | -42.7% | -32.0% | -10.7% |
| Current Ratio | 5.79 | 2.84 | +2.95 |
| Debt / Equity | — | 0.28 | — |